In this issue of Quick Notes, we provide an eyebrow-raising peek at the European Medicines Agency’s newly announced 2025 marketing authorization fees as well as some insight on how the EU wants to ensure a steady supply of medical radioisotopes and two new Q & A docs –one for biosimilars and one for medical devices that incorporate a medicinal product.
Source: Drug Industry Daily